Savara Inc. (SVRA) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Savara Inc. (SVRA) stock. It shows the current stock price, its daily change, and offers historical data views. The page also mentions the lack of analyst ratings and earnings information for the company, while promoting trading tools and educational content.
SVRA Technical Analysis & Stock Price Forecast
The technical analysis for Savara Inc. (SVRA) shows an overall consensus of "Strong Sell" based on aggregating 14 technical signals, with 8 indicating sell and 6 indicating buy. While some moving averages suggest a "Buy" signal, the MACD, Stochastic Oscillator, and CCI point towards a "Sell" or "Neutral" outlook. SVRA is currently trading above its 60-day and 200-day moving averages, with key resistance at $5.69 and support at $4.8.
Why Savara (SVRA) Is Up 5.7% After EMA Validates MOLBREEVI Application And FDA Priority Review
Savara Inc. saw its stock rise by 5.7% after the European Medicines Agency (EMA) validated its Marketing Authorization Application for MOLBREEVI, and the U.S. FDA continues its Priority Review for the drug. MOLBREEVI, targeting autoimmune pulmonary alveolar proteinosis, could be the first approved treatment for this rare disease in major Western markets, despite the company's past losses and ongoing financial considerations. The regulatory progress significantly reduces uncertainty around timelines and shapes Savara's investment narrative moving forward.
Jefferies reiterates Savara stock Buy rating on approval confidence
Jefferies has reiterated a Buy rating and $10.50 price target for Savara (NASDAQ:SVRA) due to high confidence in the regulatory approval of its Molbreevi treatment for autoimmune pulmonary alveolar proteinosis lung disease. The firm projects $500 million in U.S. peak sales and a potential EU approval by Q1 2027, with the stock currently trading at $5.05 after a 77% return over the past year. Regulatory hurdles have been addressed, and both the FDA and EMA are progressing with Molbreevi's applications without an advisory committee for the former.
Citizens reiterates Savara stock rating on regulatory progress
Citizens has reiterated a Market Outperform rating and a $10.00 price target for Savara (NASDAQ:SVRA) due to strong regulatory progress for its drug, Molbreevi. The firm projects high approval probability and blockbuster sales potential, with regulatory reviews underway in the U.S., EU, and U.K. Other analysts like Jefferies and H.C. Wainwright also maintain positive ratings and price targets.
Savara Inc announced that its Marketing Authorization Application (MAA) for Molbreevi*, a treatment for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP), has been formally validated by the European Medicines Agency (EMA).
Savara Inc. announced that its Marketing Authorization Application (MAA) for Molbreevi*, a treatment for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP), has been formally validated by the European Medicines Agency (EMA). This validation officially initiates the regulatory review process for the drug in the European market. This development offers new hope for patients suffering from this rare respiratory disease.
Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for MOLBREEVI* to treat autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP). This validation means the EMA's review process has begun, with a decision anticipated in Q1 2027. MOLBREEVI is also under Priority Review with the U.S. FDA and has received various expedited designations from regulatory bodies.
Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of "Moderate Buy" from Brokerages
Savara Inc. (NASDAQ:SVRA) has received a "Moderate Buy" consensus rating from nine brokerages, with an average 1-year analyst target price of $9.00 against a recent share price of $5.25. Institutional investors like Polar Capital and RTW Investments significantly increased their positions in Q4, with about 87.93% of the stock held by hedge funds and other institutional investors. Savara, a clinical-stage biopharma company, however, missed its latest quarterly EPS estimate and analysts project a -0.45 EPS for the current fiscal year.
Savara (SVRA) to Release Earnings on Tuesday
Savara (SVRA) is expected to announce its Q4 2025 earnings before market open on Tuesday, March 31st, with analysts forecasting an EPS loss of ($0.12). The company's stock trades within a one-year range of $1.89–$7.01 and has a market capitalization of $1.04 billion. While Wall Street holds mixed views, the average rating is "Moderate Buy" with a $9.00 target price.
Savara Reports 2025 Results, Advances MOLBREEVI Toward Approval
Savara Inc. reported its fourth-quarter and full-year 2025 financial results, highlighting a net loss for both periods. The company is actively advancing its lead product candidate, MOLBREEVI, for autoimmune pulmonary alveolar proteinosis, with a Biologics License Application filed with the FDA and a target decision date of August 22, 2026, alongside submissions in Europe and the UK. Savara also details its financial position, including significant cash reserves and access to additional non-dilutive capital to support the potential global commercial launch of MOLBREEVI.
Savara Inc devrait afficher une perte de 12 cents par action - Earnings AVANT-PAPIER
Savara Inc. (SVRA) is expected to report an unchanged quarterly revenue with an estimated loss of 12 cents per share for the period ending June 30, 2025. Analysts have a "buy" rating on the stock with a median 12-month price target of $7.50, significantly higher than its last closing price. The company has a history of both beating and missing earnings estimates in previous quarters.
Savara (SVRA) CFO exercises stock options and ends with 536,032 shares
Savara Inc.'s Chief Financial Officer, David L. Lowrance, exercised stock options on March 18, 2026, acquiring 366,747 shares of common stock. To cover exercise costs and tax obligations, 116,760 shares were withheld by the issuer. Following these transactions, Lowrance directly owned 536,032 shares of Savara common stock.
Will Advancing MOLBREEVI and a New HQ Lease Change Savara's (SVRA) Narrative?
Savara Inc. recently reported a Q4 2025 net loss of US$32.24 million and signed a new six-year headquarters lease, while its lead therapy MOLBREEVI is advancing with the FDA confirming no advisory committee is needed and marketing applications progressing in Europe and the U.K. The company's investment narrative hinges on MOLBREEVI's success as a commercial product and managing cash burn, with regulatory outcomes and financing needs representing key risks. A Simply Wall St valuation report suggests Savara may be overvalued.
FY2026 Earnings Estimate for Savara Issued By HC Wainwright
HC Wainwright has revised its earnings per share estimates for Savara (NASDAQ:SVRA) for FY2026, lowering it from ($0.39) to ($0.49), while reaffirming a "Buy" rating. The firm also adjusted FY2027 and FY2028 estimates, indicating a delay in profitability. Savara currently holds a "Moderate Buy" consensus rating with an average target price of $9.00, trading around $5.15 per share.
HC Wainwright Comments on Savara's Q1 Earnings (NASDAQ:SVRA)
HC Wainwright analyst A. Fein projects Savara (NASDAQ: SVRA) to have a Q1 2026 EPS of ($0.13), maintaining a "Buy" rating and forecasting improved earnings for FY2029 ($0.41) and FY2030 ($0.72). Despite a Q1 EPS miss, Savara holds a consensus "Moderate Buy" rating with a target price of $9.00. Institutional ownership is high at 87.9%, with significant increases from VR Adviser and Vanguard, and new stakes from Polar Capital and RTW.
H.C. Wainwright Maintains Buy on Savara Inc. (SVRA) March 2026
H.C. Wainwright has reiterated its Buy rating on Savara Inc. (SVRA), citing the company's strong position ahead of its August PDUFA date. The market's reaction was muted, with only a 0.48% intraday change. This maintained rating signals continued positive sentiment, though investors should be mindful of the inherent regulatory risks and the binary nature of FDA outcomes regarding the PDUFA decision.
Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch
H.C. Wainwright & Co. reiterated a Buy rating and US$10.00 price target for Savara Inc. (SVRA:NASDAQ), anticipating a mid-2026 launch for its drug Molbreevi. The regulatory path has been de-risked by the FDA's decision not to convene an Advisory Committee, leading to growing commercial preparations targeting 1,700 accounts and 4,500 healthcare professionals for the rare autoimmune PAP market. Analysts project Molbreevi to generate $24.4 million in revenue in 2026, growing to $69.5 million in 2027, with profitability modeled for 2028.
H.C. Wainwright reiterates Savara stock rating, $10 target By Investing.com
H.C. Wainwright has reiterated a Buy rating for Savara (NASDAQ:SVRA) with a $10.00 price target, citing a 95% upside from the current stock price. The biotech company's Molbreevi drug is tracking toward potential FDA approval, with a PDUFA date of August 22, 2026, and the company has begun building a launch-ready infrastructure. Wall Street analysts maintain a Strong Buy consensus, and Savara has secured a loan agreement for up to $105 million contingent upon Molbreevi's FDA approval.
VR Adviser Adds Over 1 Million Savara Shares
VR Adviser, LLC significantly increased its stake in Savara (NASDAQ:SVRA) by over 1 million shares in Q4, bringing its total holding to 13.7 million shares valued at $82.9 million. This investment now represents 4.1% of the fund's assets under management, reflecting a strong belief in Savara's continued stock performance after a 96.4% gain last year. The article highlights that Savara is a high-risk clinical-stage biotechnology company with no approved products or current revenue, emphasizing that its stock performance is tied to regulatory approval news for its lead candidate, molgramostim.
SVRA SEC Filings - Savara Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Savara Inc. (SVRA) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event filings (8-K), and insider trading forms. It highlights recent filings detailing public offerings, royalty funding agreements for its lead drug MOLBREEVI, and updates on its financial performance and regulatory advancements. Stock Titan uses AI-powered summaries to help investors understand the significance of these complex disclosures.
SVRA - Savara Inc Latest Stock News & Market Updates
This page provides the latest news and market updates for Savara Inc. (SVRA), a clinical-stage biopharmaceutical company focusing on rare respiratory diseases. Key updates cover clinical developments for its lead program MOLBREEVI, regulatory milestones, financial activities such as public offerings and royalty agreements, and corporate announcements including participation in investor conferences. The content also includes historical news items regarding public offerings, pipeline updates, and conference participations from late 2020 and early 2021.
Savara 10-K: $0M Revenue, $0.00 EPS; $118.8M Net Loss
Savara (SVRA) reported zero product revenue and a net loss of $118.8 million for the year ended December 31, 2025, as stated in its 10-K filing. The company's financials reflect ongoing investments in development and regulatory activities, particularly for MOLBREEVI, which recently received Priority Review from the FDA after resubmitting its BLA. Savara is focusing on the potential approval and commercialization of MOLBREEVI following positive clinical trial results.
Savara (NASDAQ: SVRA) details new Yardley headquarters lease terms
Savara Inc. (NASDAQ: SVRA) has signed a new lease for its headquarters in Yardley, Pennsylvania, securing approximately 10,795 square feet of office space. The lease term begins on July 1, 2026, and extends through December 1, 2031, with an option for a five-year extension. The company will pay monthly base rent starting at approximately $28,337, with annual increases and a total aggregate base rent of about $1,780,900, including five months of rent abatement.
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
Savara Inc. announced its fourth quarter and full-year 2025 financial results, highlighting significant progress in the MOLBREEVI development program for autoimmune PAP. The company reported regulatory milestones including the FDA filing of a BLA with Priority Review and a PDUFA date of August 22, 2026, along with submissions to European regulatory agencies. With approximately $236 million in cash and access to additional non-dilutive capital, Savara believes it is well-capitalized for a global commercial launch of MOLBREEVI.
Earnings Flash (SVRA) Savara Posts Q4 Loss $0.13 a Share, vs. FactSet Est of $0.12 Loss
Savara Inc. reported a Q4 loss of $0.13 per share, which is slightly higher than the FactSet estimate of a $0.12 loss. The company also announced its earnings results for the full year ended December 31, 2025. Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases.
How FDA’s No-Advisory-Committee Path for MOLBREEVI Could Shape Savara (SVRA) Investors’ Outlook
Savara recently announced that the FDA's Day 74 Letter for its MOLBREEVI Biologics License Application indicated no Advisory Committee meeting is planned, setting a PDUFA target action date of August 22, 2026. This streamlined U.S. review, alongside progressing European and U.K. marketing applications, highlights MOLBREEVI's central role in Savara's strategy. The article discusses how this regulatory momentum influences Savara's investment narrative, emphasizing that while process uncertainty is reduced, the company's reliance on a single product and associated financing risks remain.
How FDA’s No-Advisory-Committee Path for MOLBREEVI Could Shape Savara (SVRA) Investors’ Outlook
Savara recently announced the FDA's Day 74 Letter for its MOLBREEVI Biologics License Application, confirming no Advisory Committee meeting is planned and setting a PDUFA target action date of August 22, 2026. This streamlined U.S. review, alongside ongoing European and U.K. marketing applications, highlights MOLBREEVI's importance to Savara as a single-product rare-disease business. The article suggests this clarity reduces procedural uncertainty but emphasizes the binary nature of regulatory risk and the company's dependence on this one program for its investment narrative.
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
Savara Inc. has announced updates on its MOLBREEVI development program for autoimmune Pulmonary Alveolar Proteinosis (PAP). The FDA has indicated no plans for an Advisory Committee meeting for the MOLBREEVI Biologics License Application (BLA), with a PDUFA target action date of August 22, 2026. Savara has also submitted the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) and plans to submit to the U.K.'s MHRA by the end of Q1 2026, aiming to bring this potential first-in-class treatment to patients with this rare lung disease.
Savara receives FDA day 74 letter for autoimmune PAP drug By Investing.com
Savara Inc. (NASDAQ:SVRA) received a Day 74 Letter from the FDA indicating that an Advisory Committee meeting will not be convened for its MOLBREEVI Biologics License Application. The company's stock has surged 111% over the past year, despite being unprofitable, and analysts have set price targets suggesting significant upside potential. MOLBREEVI, a treatment for autoimmune pulmonary alveolar proteinosis, has received several fast-track and orphan drug designations and is currently under review by multiple regulatory agencies.
Savara Inc (NASDAQ: SVRA) recently announced that it has received a Day 74 letter from the U.S. Food and Drug Administration (FDA).
Savara Inc (NASDAQ: SVRA) has received a Day 74 letter from the U.S. Food and Drug Administration (FDA) indicating no plans for an advisory committee meeting. This suggests a potentially accelerated regulatory approval process for the company's R&D project. Savara will maintain close communication with the FDA as the drug review progresses.
Savara receives FDA day 74 letter for autoimmune PAP drug
Savara Inc. received a Day 74 Letter from the FDA, indicating that an Advisory Committee meeting will not be convened for its MOLBREEVI Biologics License Application for autoimmune pulmonary alveolar proteinosis. The FDA's review of MOLBREEVI is ongoing, with a target action date of August 22, 2026. The company is also seeking approval in Europe and the UK for this drug, which has received various expedited designations.
Savara Inc (NASDAQ: SVRA) recently announced that it has received a Day 74 letter from the U.S. Food and Drug Administration (FDA).
Savara Inc. (NASDAQ: SVRA) has received a Day 74 letter from the FDA, indicating the agency has no current plans to convene an advisory committee meeting for its drug. This development suggests a potentially accelerated regulatory approval process for Savara's R&D project. The company plans to continue close communication with the FDA as the review progresses.
Savara receives FDA day 74 letter for autoimmune PAP drug
Savara Inc. received a Day 74 Letter from the FDA, indicating that an Advisory Committee meeting will not be convened for its MOLBREEVI Biologics License Application, which targets autoimmune pulmonary alveolar proteinosis. The FDA's review for MOLBREEVI, a drug with Fast Track and Breakthrough Therapy designations, is ongoing with a target action date of August 22, 2026. Despite being unprofitable, Savara maintains a "FAIR" financial health rating and analysts project significant upside potential for its stock.
Savara Inc. Confirms Participation in 2026 Citizens Life Sciences Conference Focused on Rare Respiratory Diseases
Savara Inc., a company specializing in therapies for rare respiratory diseases, has announced its participation in the 2026 Citizens Life Sciences Conference. The event will gather industry leaders, researchers, and companies to discuss advancements and innovations in life sciences. Savara's involvement underscores its commitment to scientific engagement and contributing to discussions on emerging trends, though specific details of their role or presentations are yet to be disclosed.
Savara Announces Participation in 2026 Citizens Life Sciences Conference
Savara Inc., a clinical-stage biopharmaceutical company, announced its management team will participate in a fireside chat at the 2026 Citizens Life Sciences Conference on March 11th in Miami, FL. The event will be webcast live and subsequently archived on the company's website. Savara focuses on rare respiratory diseases, with its lead program MOLBREEVI in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Why Savara (SVRA) Is Up 5.4% After FDA Grants Priority Review To MOLBREEVI Application
Savara Inc. (SVRA) saw its stock rise by 5.4% after the FDA granted Priority Review to its Biologics License Application for MOLBREEVI, intended to treat autoimmune pulmonary alveolar proteinosis (autoimmune PAP). This decision sets a PDUFA action date for August 22, 2026, solidifying a critical milestone for the single-asset biotech company. While reducing some regulatory uncertainty, the company's investment narrative remains largely dependent on MOLBREEVI's approval, with ongoing concerns about cash burn and potential stock volatility around the FDA decision.
Savara’s MOLBREEVI BLA Receives FDA Priority Review
Savara Inc. announced that the FDA has granted Priority Review to its Biologics License Application (BLA) for MOLBREEVI, a treatment for autoimmune pulmonary alveolar proteinosis (PAP), setting a target action date of August 22, 2026. This designation recognizes the drug's potential to significantly improve treatment for serious conditions. MOLBREEVI has also received other expedited designations from the FDA and EMA.
SVRA PE Ratio & Valuation, Is SVRA Overvalued
This article analyzes Savara Inc (SVRA) valuation, indicating it is currently in the "Fair zone" based on its forward P/S ratio. It highlights that SVRA's current P/B ratio is significantly higher than its 3-year and 5-year averages, while its Forward FCF yield is lower. The analysis also compares SVRA's P/S ratio to its competitors, suggesting that its premium might be unsustainable given its revenue growth.
SVRA Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Savara Inc. (SVRA), including its income statement, balance sheet, and cash flow statement, derived from SEC filings. Key financial metrics for fiscal year 2024 show negative performance across EBITDA, free cash flow, and net income, with a low Piotroski F-Score and earnings quality. The company's cash runway is estimated at approximately two months based on current burn rates.
Citizens reiterates Savara stock rating on likely FDA approval By Investing.com
Citizens reiterated a Market Outperform rating and a $10.00 price target for Savara (NASDAQ:SVRA), citing a 90% probability of FDA approval for its drug Molbreevi, which treats aPAP. The firm views the Priority Review status as a strong indicator of the FDA's recognition of the unmet need. Savara's stock has seen a 106% return over the past year, reflecting market optimism, while the company prepares for a Life Sciences Conference with Citizens to discuss Molbreevi's potential and launch preparations.
Is FDA Priority Review for MOLBREEVI Reshaping the Investment Case for Savara (SVRA)?
Savara Inc. recently announced that the FDA granted Priority Review for its Biologics License Application for MOLBREEVI, setting a PDUFA action date of August 22, 2026. This development significantly sharpens Savara’s investment profile by creating a defined regulatory timeline and linking capital availability to MOLBREEVI's approval. While this status is material given strong share gains, it also raises the stakes, making execution missteps or an adverse FDA outcome more consequential for the company.
Is FDA Priority Review for MOLBREEVI Reshaping the Investment Case for Savara (SVRA)?
Savara Inc. received FDA Priority Review for its Biologics License Application for MOLBREEVI, targeting autoimmune pulmonary alveolar proteinosis, with a PDUFA action date of August 22, 2026. This development significantly sharpens the company's investment narrative by providing a defined regulatory timeline and linking it to a critical debt facility. While the BLA status raises the stakes, especially given the company's current losses and diverse valuation estimates, it also highlights MOLBREEVI's potential for an underserved patient population.
Citizens reiterates Savara stock rating on likely FDA approval
Citizens reiterated a Market Outperform rating and $10.00 price target for Savara (NASDAQ:SVRA) due to the likely FDA approval of Molbreevi for autoimmune pulmonary alveolar proteinosis (aPAP). The firm assigns a 90% probability of approval, citing a recent pulmonologist survey predicting strong uptake, and notes the stock has already seen a 106% return over the past year. Savara's management is set to attend Citizens' Life Sciences Conference to discuss the aPAP opportunity and launch preparations further.
Savara Grants Inducement Equity Awards to New Employee
Savara Inc. (Nasdaq: SVRA) has granted stock options and restricted stock units (RSUs) covering a total of 15,000 shares to a new employee. These inducement awards were approved by the Compensation Committee under the company's 2021 Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The grants include options to purchase 7,500 shares at an exercise price of $5.27 and 7,500 RSUs, both vesting over time subject to continued employment.
Citizens reiterates Savara stock rating on likely FDA approval By Investing.com
Citizens reiterated a Market Outperform rating and $10.00 price target for Savara (NASDAQ:SVRA) shares, citing a 90% probability of FDA approval for Molbreevi due to Priority Review status and high unmet need in aPAP. The company's stock has seen a 106% return over the past year, with Citizens predicting Molbreevi could be a blockbuster drug. Savara recently had its Biologics License Application for MOLBREEVI accepted by the FDA with Priority Review, and amended its loan agreement with Hercules Capital to access up to $105 million upon FDA approval.
Citizens reiterates Savara stock rating on likely FDA approval By Investing.com
Citizens has reaffirmed its "Market Outperform" rating and a $10.00 price target for Savara (NASDAQ:SVRA) due to the high likelihood of FDA approval for its treatment, Molbreevi, for autoimmune pulmonary alveolar proteinosis (aPAP). The firm assigns a 90% probability of success for approval, citing the FDA's Priority Review and strong anticipated market uptake. This optimism follows Savara's resubmission of its Biologics License Application, with other analysts also reiterating positive ratings and increased price targets.
Major Savara Inc. (SVRA) holder reports 6.1% stake in Schedule 13G/A
TCG Crossover entities and Chen Yu have reported a beneficial ownership of 12,362,205 shares of Savara Inc. common stock, which represents 6.1% of the company's outstanding shares. This updated Schedule 13G/A filing indicates that while they hold significant voting and dispositive power through TCG Crossover Fund I, L.P. and its general partner TCG Crossover GP I, LLC, their intention is not to change or influence the control of Savara. The report is based on 203,467,845 shares outstanding as of November 12, 2025.
Savara, Inc. (SVRA) Stock Analysis: Biotech Player With An 89% Upside Potential
Savara, Inc. (SVRA) is a clinical-stage biopharmaceutical company focusing on rare respiratory diseases, with its lead candidate molgramostim in Phase 3 trials. Despite not yet generating revenue and operating at a loss, the company has significant investor interest with a $1.16 billion market cap and an 89.03% potential upside according to analysts. Strong analyst sentiment, with an average target price of $10.81, highlights confidence in its long-term potential, making it a high-risk, high-reward investment for those with a greater risk tolerance.
FDA accepts Savara’s drug application for rare lung disease
The FDA has accepted Savara Inc.'s Biologics License Application for MOLBREEVI, a drug aimed at treating autoimmune pulmonary alveolar proteinosis, granting it Priority Review with a target action date of August 22, 2026. This positive regulatory development follows significant stock performance and analyst support, with the company also planning submissions to European agencies. While Savara is currently unprofitable, its liquid assets exceed short-term obligations, providing financial flexibility as it moves toward potential commercialization.
FDA Grants Priority Review to Savara's (SVRA) Molbreevi BLA
Savara Inc. (SVRA) has received FDA priority review for its Molbreevi Biologics License Application, a significant step for its drug targeting a rare lung condition, with a decision expected by August 22. Despite this positive development, the company currently reports zero revenue and negative EPS, indicating a pre-commercial stage with financial challenges. While institutional ownership is high, Savara's valuation metrics and recent insider selling suggest investors should approach with caution, weighing the drug's potential against inherent financial and sector-specific risks in biotechnology.
